✦ LIBER ✦

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

✍ Scribed by Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; David Pound; Mitchell N Davis; Joseph S Galati; Stuart C Gordon; Natarajan Ravendhran; Lorenzo Rossaro; Frank H Anderson; Ira M Jacobson; Raymond Rubin; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Eirum Chaudhri; Janice K Albrecht

Book ID: 117306870
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 378 KB
Volume: 376
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(10)60934-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sofosbuvir with pegylated interferon alf

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

✍ Kowdley, Kris V; Lawitz, Eric; Crespo, Israel; Hassanein, Tarek; Davis, Mitchell 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 241 KB

1096 ASUNAPREVIR (ASV; BMS-650032), AN N

1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

✍ Bronowicki, J.-P.; Pol, S.; Thuluvath, P.; Larrey, D.; Martorell, C.T.; Rustgi, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Sofosbuvir in combination with peginterf

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

✍ Lawitz, Eric; Lalezari, Jay P; Hassanein, Tarek; Kowdley, Kris V; Poordad, Fred 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 276 KB

1163 A PHASE 2A STUDY OF BMS-791325, AN

1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

✍ Tatum, H.; Thuluvath, P.; Lawitz, E.; Martorell, C.T.; Demicco, M.; Cohen, S.; R 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

1195 BMS-650032, AN NS3 INHIBITOR, IN CO

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

✍ Bronowicki, J.-P.; Pol, S.; Thuluvath, P.J.; Larrey, D.; Martorell, C.T.; Rustgi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Sofosbuvir and ledipasvir fixed-dose com

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

✍ Lawitz, Eric; Poordad, Fred F; Pang, Phillip S; Hyland, Robert H; Ding, Xiao; Mo 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 400 KB